JP2015520383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520383A5 JP2015520383A5 JP2015516117A JP2015516117A JP2015520383A5 JP 2015520383 A5 JP2015520383 A5 JP 2015520383A5 JP 2015516117 A JP2015516117 A JP 2015516117A JP 2015516117 A JP2015516117 A JP 2015516117A JP 2015520383 A5 JP2015520383 A5 JP 2015520383A5
- Authority
- JP
- Japan
- Prior art keywords
- cytokine
- subject
- pdgf
- concentration
- reference level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004127 Cytokines Human genes 0.000 claims 36
- 108090000695 Cytokines Proteins 0.000 claims 36
- 238000000034 method Methods 0.000 claims 21
- 210000004369 blood Anatomy 0.000 claims 18
- 239000008280 blood Substances 0.000 claims 18
- 108010081589 Becaplermin Proteins 0.000 claims 11
- 201000008482 osteoarthritis Diseases 0.000 claims 10
- 108010000685 platelet-derived growth factor AB Proteins 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 8
- 102400001368 Epidermal growth factor Human genes 0.000 claims 5
- 101800003838 Epidermal growth factor Proteins 0.000 claims 5
- 229940116977 epidermal growth factor Drugs 0.000 claims 5
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 4
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 4
- 210000001772 blood platelet Anatomy 0.000 claims 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000002381 plasma Anatomy 0.000 claims 4
- 210000004623 platelet-rich plasma Anatomy 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102400000027 Interleukin-1 receptor type 2, soluble form Human genes 0.000 claims 1
- 101800001003 Interleukin-1 receptor type 2, soluble form Proteins 0.000 claims 1
- 206010023230 Joint stiffness Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655322P | 2012-06-04 | 2012-06-04 | |
| US61/655,322 | 2012-06-04 | ||
| PCT/US2013/044075 WO2013184660A1 (en) | 2012-06-04 | 2013-06-04 | Methods for diagnosing osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520383A JP2015520383A (ja) | 2015-07-16 |
| JP2015520383A5 true JP2015520383A5 (enExample) | 2016-07-28 |
Family
ID=48626668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516117A Pending JP2015520383A (ja) | 2012-06-04 | 2013-06-04 | 変形性関節症を診断するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150141332A1 (enExample) |
| EP (1) | EP2856171A1 (enExample) |
| JP (1) | JP2015520383A (enExample) |
| CN (1) | CN104471406A (enExample) |
| WO (1) | WO2013184660A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US9833474B2 (en) | 2013-11-26 | 2017-12-05 | Biomet Biologies, LLC | Methods of mediating macrophage phenotypes |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| CN111855999A (zh) * | 2020-06-02 | 2020-10-30 | 广东省药品检验所（广东省药品质量研究所、广东省口岸药品检验所） | 一种化妆品中rhEGF快速检测试纸卡、试剂盒及其检测方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120030593A1 (en) | 1995-11-13 | 2012-02-02 | Lakshmi Arunachalam | Method and apparatus for enabling real-time bi-directional transactions on a network |
| JP4344436B2 (ja) * | 1999-08-24 | 2009-10-14 | 生化学工業株式会社 | 変形性関節症の検出方法 |
| DE602004030586D1 (de) * | 2003-09-15 | 2011-01-27 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| CN1977049A (zh) * | 2004-04-26 | 2007-06-06 | 儿童医疗中心有限公司 | 用于检测疾病的血小板生物标志物 |
| US7662573B2 (en) * | 2004-08-18 | 2010-02-16 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for evaluating osteoarthritis risk |
| EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
| US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US20110306512A1 (en) * | 2008-06-25 | 2011-12-15 | Dxterity Diagnostics | Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis |
| US20110052561A1 (en) | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| WO2011031553A2 (en) | 2009-08-27 | 2011-03-17 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
-
2013
- 2013-06-04 WO PCT/US2013/044075 patent/WO2013184660A1/en not_active Ceased
- 2013-06-04 CN CN201380037434.2A patent/CN104471406A/zh active Pending
- 2013-06-04 EP EP13729204.1A patent/EP2856171A1/en not_active Withdrawn
- 2013-06-04 JP JP2015516117A patent/JP2015520383A/ja active Pending
- 2013-06-04 US US14/405,726 patent/US20150141332A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520383A5 (enExample) | ||
| Hamaguchi et al. | Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults | |
| ES2656897T3 (es) | Procedimientos de predicción del riesgo de desarrollar hipertensión | |
| Kim et al. | Simple age specific cutoff value for sarcopenia evaluated by computed tomography | |
| JP2014521308A5 (enExample) | ||
| Finn et al. | Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer | |
| Hant et al. | Pulmonary manifestations of scleroderma and mixed connective tissue disease | |
| Bessa et al. | Pulmonary arterial hypertension: use of delayed contrast-enhanced cardiovascular magnetic resonance in risk assessment | |
| Sabatino et al. | The impact of muscle mass and myosteatosis on mortality in critically ill patients with Sars-Cov2-related pneumonia | |
| Huang et al. | Acute cardiac dysfunction after short-term diesel exhaust particles exposure | |
| Vonk-Noordegraaf et al. | Noninvasive assessment and monitoring of the pulmonary circulation | |
| Hollier et al. | Validity of arterialised-venous PCO2, pH and bicarbonate in obesity hypoventilation syndrome | |
| Coskun et al. | Hepatic toxocariasis: a rare cause of right upper abdominal pain in the emergency department | |
| JP2012521549A5 (enExample) | ||
| RU2011142612A (ru) | Биомаркер для мониторинга пациентов | |
| Skibsted et al. | The association of near infrared spectroscopy-derived StO2 measurements and biomarkers of endothelial activation in sepsis | |
| Amarapurkar et al. | Budd–chiari syndrome following laparoscopic cholecystectomy | |
| JP2015049050A5 (enExample) | ||
| JP2012127879A (ja) | 腎症の進行度の判定方法並びに線維化抑制剤。 | |
| Osbak et al. | Non-invasive measurements of cardiac output in atrial fibrillation: Inert gas rebreathing and impedance cardiography | |
| Nakai et al. | Correlation between soluble interleukin-2 receptor levels and modified Rodnan total skin thickness scores in a patient with generalized morphea: a case report | |
| RU2290645C1 (ru) | Способ оценки активности воспалительного процесса при псориазе | |
| Wang et al. | Comparison of thoracic bioimpedance with acetylene uptake for measuring cardiac output | |
| Baker | Correlation between biochemical analysis and periodontal health status and tooth loss in chronic renal failure patients | |
| CALLARI | Treatment adherence in bipolar disorder: the role of serum-salivary bioequivalence in drug monitoring |